Prevalence and Risk Factors of self-reported dry eye in Brazil using a short symptom questionnaire
2018 · Scientific Reports · 73 citations
https://doi.org/10.1038/s41598-018-20273-9
E
Eliana Miranda
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
193
Papers
1.7K
Citations
20
h-index
33
i10-index
Eliana Miranda is an academic researcher from Universidade Estadual de Campinas (UNICAMP). The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Hematopoietic Stem Cell Transplantation & Chronic Myeloid Leukemia Treatments. The author has an h-index of 20, co-authored 165 publications.
ORCID: 0000-0002-7177-7664Papers by this author
worksProposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma
2019 · Scientific Reports · 43 citations
https://doi.org/10.1038/s41598-019-52740-2
Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (<scp>EDI‐PIO</scp>) in chronic myeloid leukemia with deep molecular response
2020 · American Journal of Hematology · 16 citations
https://doi.org/10.1002/ajh.25986
Adrenocortical tumors associated with the TP53 p.R337H germline mutation can be identified during child-care consultations
2017 · Jornal de Pediatria · 14 citations
https://doi.org/10.1016/j.jped.2017.06.009
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
2024 · Blood Advances · 8 citations
https://doi.org/10.1182/bloodadvances.2024014674
Pioglitazone Did Not Affect PPAR-Γ, STAT5, HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response
2019 · Blood · 7 citations
https://doi.org/10.1182/blood-2019-128265
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat